1. P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. (21st January 2022) Authors: Buisson, A; Nachury, M; Reymond, M; Yzet, C; Wils, P; Payen, L; Manlay, L; Pereira, B; Fumery, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗